Arcus Biosciences (RCUS) Free Cash Flow (2017 - 2026)

Arcus Biosciences' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$138.0 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 3.76% year-over-year to -$138.0 million in Q1 2026; TTM through Mar 2026 was -$489.0 million, a 75.9% decrease from a year earlier, with the FY2025 full-year figure at -$484.0 million, down 227.03% from the prior year.
• Free Cash Flow eased to -$138.0 million in Q1 2026 per RCUS's latest filing, from -$121.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $651.0 million in Q1 2022 and bottomed at -$138.0 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$94.0 million (2024), against an average of -$39.3 million.
• Across the five-year window, Free Cash Flow soared 1042.11% in 2022 and sank 4333.33% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$72.0 million in 2022, then sank by 38.89% to -$100.0 million in 2023, then grew by 6.0% to -$94.0 million in 2024, then fell by 28.72% to -$121.0 million in 2025, then retreated by 14.05% to -$138.0 million in 2026.
• Per Business Quant, the three latest RCUS Free Cash Flow figures stand at -$138.0 million (Q1 2026), -$121.0 million (Q4 2025), and -$97.0 million (Q3 2025).